Natco Pharma Ltd Share Price – NSE  /  BSE

Pharmaceuticals, Small Cap

Natco Pharma Ltd gained for a fifth straight session today. The stock is quoting at Rs 1154, up 5.12% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.34% on the day, quoting at 23337.55. The Sensex is at 76691.49, up 0.26%. Natco Pharma Ltd has gained around 18.42% in last one month.

Meanwhile, Nifty Pharma index of which Natco Pharma Ltd is a constituent, has gained around 4.56% in last one month and is currently quoting at 19774.7, up 0.14% on the day. The volume in the stock stood at 11.26 lakh shares today, compared to the daily average of 10.12 lakh shares in last one month.

The PE of the stock is 15.05 based on TTM earnings ending March 24.

Powered by Capital Market - Live News

Natco Pharma Ltd rose for a third straight session today. The stock is quoting at Rs 1084.7, up 4.93% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 1.78% on the day, quoting at 23226.9. The Sensex is at 76478.93, up 1.87%. Natco Pharma Ltd has added around 10.12% in last one month.

Meanwhile, Nifty Pharma index of which Natco Pharma Ltd is a constituent, has added around 3.55% in last one month and is currently quoting at 19232.1, up 1.5% on the day. The volume in the stock stood at 12.84 lakh shares today, compared to the daily average of 8.92 lakh shares in last one month.

The PE of the stock is 14.17 based on TTM earnings ending March 24.

Powered by Capital Market - Live News

Net profit of Natco Pharma rose 40.07% to Rs 386.30 crore in the quarter ended March 2024 as against Rs 275.80 crore during the previous quarter ended March 2023. Sales rose 18.98% to Rs 1068.30 crore in the quarter ended March 2024 as against Rs 897.90 crore during the previous quarter ended March 2023.

For the full year,net profit rose 94.09% to Rs 1388.30 crore in the year ended March 2024 as against Rs 715.30 crore during the previous year ended March 2023. Sales rose 47.72% to Rs 3998.80 crore in the year ended March 2024 as against Rs 2707.10 crore during the previous year ended March 2023.

Powered by Capital Market - Live News

Profit before tax for March 2024 quarter stood at Rs 477.6 crore, up 47.23% from Rs 324.4 crore posted in same quarter last year.

Total expenses rose 5.01% to Rs 632.7 crore in Q4 FY24 over Q4 FY23. Cost of materials consumed was Rs 127.6 crore (up 12.78% YoY) while employee benefits expense stood at Rs 142.5 crore (up 19.85% YoY) and other expenses was Rs 285.9 crore (up 57.52% YoY) during the period under review.

For FY24, the pharmaco’s consolidated net profit surged 94.09% to Rs 1,388.3 crore on 46.78% jump in total income to Rs 4,126.9 crore over FY23.

Natco Pharma is engaged in the business of pharmaceuticals which comprises research and development, manufacturing and selling of bulk drugs and finished dosage formulations. The company has manufacturing facilities in India which caters to both domestic and international markets including regulated markets like United States of America and Europe.

The scrip hit 52-week high of Rs 1,108.95 in today’s intraday session.

Powered by Capital Market - Live News